Merck & Co., Inc. (NYSE:MRK) and US biotech startup Moderna Therapeutics have moved their 2016 partnership a step further by agreeing to share antigen mRNA cancer vaccines including mRNA-5671. Under the initial partnership, the two companies agreed to jointly develop and commercialize novel personalized messenger RNA (mRNA) cancer vaccines.
Moderna started developing mRNA-5671 in 2017. Both companies have agreed to partner in advancing mRNA-5671 in human studies in addition to jointly conducting studies with additional immuno-oncology therapies.
In a statement, Merck Research Laboratories president Dr Roger Perlmutter said that their work with the PD-1-specific antibody Keytruda has proved that augmentation of immune responses offers promising results in cancer treatment. He noted that the two companies are working on expanding their partnership in exploring and testing mRNA cancer vaccines.
Under the new partnership deal, Merck will be tasked with the clinical development of mRNA-5671 plus all the cost that will come with it. On the other hand, Moderna will be in charge of clinical supply and will also cover all associated costs. After the completion of the human proof-of-concept (hPOC) studies, Merck intends to take over the development and marketing of mRNA-5671 after paying a certain amount of fees to Moderna.
Deal includes $125 million investment by Merck
In yet another deal, Merck has announced that it will make another $125 million investment in Moderna in the new series H preferred equity.
The two companies will equally share the proceeds as well as the costs that will come from mRNA-5671. Additionally, as part of the agreement, the two companies will launch and partner on other programs that entail development of antigen mRNA cancer vaccines.
Moderna chief executive Stéphane Bancel while commenting on the deal said that they are very happy to extend their partnership with Merck as well as advance the novel mRNA-based KRAS cancer vaccine. He added that the company’s mRNA platform will help in attaining the KRAS target, which has been a big challenge.
Moderna also has a partnership with AstraZeneca, which increase its holding in the company in 2016 to 9%. Additionally, it has a research agreement with Vertex.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.